|
Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It binds to interleukin-6.〔(International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy) ), ''World Health Organization''.〕〔(Siltuximab mechanism of action )〕 Siltuximab has been investigated for the treatment of metastatic renal cell cancer, prostate cancer, and Castleman's disease,〔(First IL-6–blocking drug nears approval for rare blood disorder ) Nature Medicine, October 7, 2013〕 among other types of cancer.〔ClinicalTrials.gov: (Siltuximab )〕 It has undergone a phase I clinical trial in patients With B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. There were encouraging results in a small trial for advanced ovarian cancer.〔(【引用サイトリンク】title=CNTO 328 Shows Promise For Ovarian Cancer In Small Clinical Trial, Say U.K. Scientists. )〕 Encouraging results have been reported from a phase II trial for relapsed or refractory multiple myeloma. On April 23, 2014, Siltuximab was FDA approved under the brand name of Sylvant〔(Sylvant official website )〕 for the treatment of patients with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) or human herpesvirus-8 (HHV-8).〔(FDA.gov press release for siltuximab approval, accessed April 24, 2014 )〕〔(Siltuximab cancer regimen & references )〕 ==Medical uses== Used for the treatment of multicentric Castleman’s disease (MCD).〔(【引用サイトリンク】url=http://www.janssenmd.com/pdf/sylvant/SYLVANT-PI.pdf )〕 A randomized double-blind placebo controlled trial demonstrated that Siltuximab treatment improved symptomatic multicenric Castleman’s disease (MCD) compared to placebo. Primary endpoints in the study included durable tumor and symptomatic response defined as complete or partial response with improvement or stabilization of disease related symptoms for at least 18 weeks. A total of 79 patients were enrolled in the study (53 assigned to siltuximab, 26 assigned to placebo. This study included HIV-negative and Human herpevisrus 8 (Kaposi's sarcoma-associated herpesvirus) seronegative patients aged 20-78 years old with symptomatic multicentric Castleman’s disease (fatigue, malaise, night sweats, peripheral sensory neuropathy, anorexia, pruritus, dyspnea, oedma, hyperhidrosis) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Siltuximab」の詳細全文を読む スポンサード リンク
|